DK2470526T3 - Forbindelser og sammensætninger som proteinkinase-inhibitorer - Google Patents

Forbindelser og sammensætninger som proteinkinase-inhibitorer

Info

Publication number
DK2470526T3
DK2470526T3 DK10748211.9T DK10748211T DK2470526T3 DK 2470526 T3 DK2470526 T3 DK 2470526T3 DK 10748211 T DK10748211 T DK 10748211T DK 2470526 T3 DK2470526 T3 DK 2470526T3
Authority
DK
Denmark
Prior art keywords
compositions
compounds
proteinkinase inhibitors
proteinkinase
inhibitors
Prior art date
Application number
DK10748211.9T
Other languages
Danish (da)
English (en)
Inventor
Shenlin Huang
Xianming Jin
Daniel Poon
Yongping Xie
Zuosheng Liu
John TELLEW
Yongqin Wan
Xing Wang
Original Assignee
Irm Llc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42782253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2470526(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Irm Llc, Novartis Ag filed Critical Irm Llc
Application granted granted Critical
Publication of DK2470526T3 publication Critical patent/DK2470526T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
DK10748211.9T 2009-08-28 2010-08-27 Forbindelser og sammensætninger som proteinkinase-inhibitorer DK2470526T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23807309P 2009-08-28 2009-08-28
US31303910P 2010-03-11 2010-03-11
PCT/US2010/046930 WO2011025927A1 (en) 2009-08-28 2010-08-27 Compounds and compositions as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
DK2470526T3 true DK2470526T3 (da) 2014-08-25

Family

ID=42782253

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14152945.3T DK2727918T3 (da) 2009-08-28 2010-08-27 Forbindelser og sammensætninger som proteinkinaseinhibitorer
DK10748211.9T DK2470526T3 (da) 2009-08-28 2010-08-27 Forbindelser og sammensætninger som proteinkinase-inhibitorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14152945.3T DK2727918T3 (da) 2009-08-28 2010-08-27 Forbindelser og sammensætninger som proteinkinaseinhibitorer

Country Status (49)

Country Link
US (12) US8501758B2 (OSRAM)
EP (2) EP2470526B1 (OSRAM)
JP (2) JP5475888B2 (OSRAM)
KR (1) KR101413392B1 (OSRAM)
CN (2) CN102725283B (OSRAM)
AR (1) AR077975A1 (OSRAM)
AU (1) AU2010286569C1 (OSRAM)
BR (1) BR112012004453B1 (OSRAM)
CA (1) CA2771775C (OSRAM)
CL (1) CL2012000340A1 (OSRAM)
CO (1) CO6612222A2 (OSRAM)
CR (1) CR20120102A (OSRAM)
CU (1) CU24110B1 (OSRAM)
CY (3) CY1118452T1 (OSRAM)
DK (2) DK2727918T3 (OSRAM)
DO (1) DOP2012000051A (OSRAM)
EA (2) EA025222B1 (OSRAM)
EC (2) ECSP12011700A (OSRAM)
ES (2) ES2492499T3 (OSRAM)
GE (1) GEP20146102B (OSRAM)
GT (1) GT201200053A (OSRAM)
HN (1) HN2012000441A (OSRAM)
HR (2) HRP20140799T1 (OSRAM)
HU (3) HUE032847T2 (OSRAM)
IL (1) IL218084A (OSRAM)
IN (1) IN2012DN02469A (OSRAM)
JO (1) JO3002B1 (OSRAM)
LT (3) LT2727918T (OSRAM)
LU (2) LUC00102I2 (OSRAM)
MA (1) MA33604B1 (OSRAM)
ME (2) ME02684B (OSRAM)
MX (1) MX2012002546A (OSRAM)
MY (1) MY156259A (OSRAM)
NI (1) NI201200029A (OSRAM)
NL (1) NL300973I2 (OSRAM)
NO (2) NO2019011I1 (OSRAM)
NZ (1) NZ598924A (OSRAM)
PE (1) PE20120861A1 (OSRAM)
PL (2) PL2727918T3 (OSRAM)
PT (2) PT2727918T (OSRAM)
RS (2) RS55568B1 (OSRAM)
SG (2) SG178351A1 (OSRAM)
SI (2) SI2727918T1 (OSRAM)
SM (3) SMT201700036T1 (OSRAM)
TN (1) TN2012000081A1 (OSRAM)
UA (1) UA112285C2 (OSRAM)
UY (1) UY32860A (OSRAM)
WO (1) WO2011025927A1 (OSRAM)
ZA (1) ZA201202020B (OSRAM)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
US8907270B2 (en) 2010-06-30 2014-12-09 Schlumberger Technology Corporation Method and apparatus for gain regulation in a gamma detector
BR112014011223A8 (pt) * 2011-11-11 2023-01-31 Novartis Ag Método de tratar uma doença proliferativa
KR102091295B1 (ko) * 2011-11-23 2020-03-19 어레이 바이오파마 인크. 제약 제제
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CN103159736B (zh) * 2011-12-10 2015-05-13 通化济达医药有限公司 取代的吡唑激酶抑制剂
WO2013096637A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9629839B2 (en) 2012-03-28 2017-04-25 Dana-Farber Cancer Institute, Inc. C-RAF mutants that confer resistance to RAF inhibitors
US9085606B2 (en) 2012-07-18 2015-07-21 Saint Louis University Beta amino acid derivatives as integrin antagonists
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
EP3574904A1 (en) 2012-08-07 2019-12-04 Array Biopharma, Inc. Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
PT2884979T (pt) 2012-08-17 2019-09-04 Hoffmann La Roche Terapêuticas combinadas para o melanoma, compreendendo a administração de cobimetinib e vemurafinib
US20150232452A1 (en) * 2012-09-19 2015-08-20 Ruga Corporation Novel raf kinase inhibitors
CA2890663A1 (en) * 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
SG11201507730UA (en) * 2013-03-21 2015-10-29 Novartis Ag Combination therapy comprising a b-raf inhibitor and a second inhibitor
TWI634114B (zh) * 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
RU2015149937A (ru) 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
EP3049442A4 (en) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
MX394252B (es) * 2013-12-20 2025-03-21 Biomed Valley Discoveries Inc Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
AU2014372166B2 (en) * 2013-12-23 2017-10-26 Novartis Ag Pharmaceutical combinations
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
DE102015103158A1 (de) 2014-03-04 2015-09-10 Bergische Universität Wuppertal Verbindungen für die Behandlung des Melanoms
CA2936962C (en) 2014-03-14 2024-03-05 Novartis Ag Antibody molecules to lag-3 and uses thereof
WO2015145388A2 (en) 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3143166A4 (en) 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3191478B1 (en) * 2014-09-12 2019-05-08 Novartis AG Compounds and compositions as raf kinase inhibitors
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
EP3662903A3 (en) 2014-10-03 2020-10-14 Novartis AG Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2964367C (en) 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
WO2017019896A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
BR112018008891A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
HK1244806A1 (zh) 2015-12-30 2018-08-17 Saint Louis University 作為過氧乙醯硝酸整聯蛋白拮抗劑的間氮雜環氨基苯甲酸衍生物
RU2615986C1 (ru) * 2016-02-25 2017-04-12 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") Замещенные метил (2-{ 4-[3-(3-метансульфониламино-2-фтор-5-хлор-фенил)-1Н-пиразол-4-ил]пиримидин-2-иламино} -этил)карбаматы, способ их получения и применения
CN109890386B (zh) 2016-06-03 2022-05-24 阵列生物制药公司 药物组合
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
EP3564232B1 (en) * 2016-12-27 2022-01-26 Riken Bmp-signal-inhibiting compound
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CN107540699A (zh) * 2017-10-16 2018-01-05 康化（上海）新药研发有限公司 一种2‑氨基‑3‑氟吡啶‑4‑硼酸盐酸盐的合成方法
JP7416716B2 (ja) 2017-12-28 2024-01-17 トラクト ファーマシューティカルズ インコーポレイテッド 円柱上皮幹細胞のための幹細胞培養系およびそれに関連した使用法
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
WO2020011141A1 (zh) * 2018-07-12 2020-01-16 深圳市塔吉瑞生物医药有限公司 一种二芳基吡唑化合物及包含该化合物的组合物及其用途
WO2020124397A1 (en) * 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. C-terminal src kinase inhibitors
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
WO2020231976A1 (en) 2019-05-16 2020-11-19 Eli Lilly And Company Triple combination of an erk1/2 inhibitor with a braf inhibitor and an egfr inhibitor for use in the treatment of brafv600e colorectal cancer
KR20220131229A (ko) 2019-12-05 2022-09-27 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) N-(3-(5-(피리미딘-4-일)티아졸-4-일)페닐)설폰아미드 화합물 및 이의 용도
PE20231651A1 (es) 2020-06-09 2023-10-17 Array Biopharma Inc Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
US20230303551A1 (en) 2020-08-13 2023-09-28 Albert Einstein College Of Medicine N-cyclyl-sulfonamides useful for inhibiting raf
WO2022074011A1 (en) 2020-10-05 2022-04-14 Pierre Fabre Medicament Combination of encorafenib and binimetinib as adjuvant treatment for resected stage ii melanoma
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
MX2023014565A (es) 2021-06-09 2024-02-08 Chugai Pharmaceutical Co Ltd Tratamiento conjunto para tratamiento contra el cancer.
CN114181197B (zh) * 2022-02-16 2022-05-06 北京康立生医药技术开发有限公司 一种治疗肠癌的药物的制备方法、制剂及纯度分析方法
CA3257280A1 (en) 2022-05-25 2023-11-30 Msd International Gmbh COMBINATION OF A BRAF INHIBITOR, AN EGFR INHIBITOR AND A PD-1 ANTAGONIST FOR THE TREATMENT OF COLORECTAL CANCER MSI-H/DMMR, WITH BRAF V600E MUTATION
WO2024163166A1 (en) * 2023-01-30 2024-08-08 5Metis, Inc. Boron containing compounds and their uses
AU2023439518A1 (en) 2023-04-06 2025-08-28 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
CN116396222A (zh) * 2023-04-10 2023-07-07 上海睿腾医药科技有限公司 一种康奈非尼中间体1-（3-氨基-1-异丙基-1h-吡唑-4-基）乙-1-酮的合成方法
WO2025003956A1 (en) 2023-06-30 2025-01-02 Pfizer Inc. High drug loading formulations of encorafenib

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4104250A (en) * 1976-08-11 1978-08-01 Borg-Warner Corporation Flame-retardant polymers with 1,3,5-triazines having halo- and halo-aryl substitutents
JPS5475888A (en) 1977-11-29 1979-06-18 Jiyasuko Kk Surgical laser
EP0184384B1 (en) 1984-12-06 1989-08-02 Pfizer Inc. Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6037136A (en) 1994-10-24 2000-03-14 Cold Spring Harbor Laboratory Interactions between RaF proto-oncogenes and CDC25 phosphatases, and uses related thereto
CA2231050A1 (en) 1995-09-07 1997-03-13 Biovail International Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5717100A (en) 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
IL127210A0 (en) 1996-05-23 1999-09-22 Applied Research Systems Compounds inhibiting the binding of raf-1 or 13-3-3 proteins to the beta-chain of il-2 pharmaceutical compositions containing them and their use
AR012634A1 (es) 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
IL132991A (en) 1997-05-22 2005-11-20 Searle & Co Substituted pyrazoles, pharmaceutical compositionscomprising them and their use as p38 inase inhibi tors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use
US6204467B1 (en) 1998-03-24 2001-03-20 Ford Global Technologies, Inc. Method and apparatus for resistive welding
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6316435B2 (en) 1999-02-24 2001-11-13 Supergen, Inc. Combination therapy for lymphoproliferative diseases
AU2331801A (en) 1999-12-23 2001-07-09 F.H. Faulding & Co. Limited Improved pharmaceutical compositions for poorly soluble drugs
US6756410B2 (en) 2000-08-30 2004-06-29 Kamal D. Mehta Induction of LDL receptor expression by extracellular-signal regulated kinase, ERK-1/2
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US20050043409A1 (en) 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
ATE374753T1 (de) 2001-12-21 2007-10-15 Vernalis Cambridge Ltd 3-(2,4)dihydroxyphenyl-4-phenylpyrazole und deren medizinische verwendung
MXPA04008893A (es) 2002-03-13 2005-06-20 Array Biopharma Inc Derivados de bencimidazol n3 alquilados como inhibidores de mek.
BRPI0414698A (pt) 2003-09-23 2006-11-28 Novartis Ag combinação de um inibidor receptor de vegf com um agente quimioterapêutico
CA2545942C (en) 2003-11-14 2012-07-10 Lorus Therapeutics Inc. Aryl imidazoles and their use as anti-cancer agents
BRPI0506760A (pt) 2004-01-09 2007-05-22 Novartis Ag derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina como inibidores de igf-ir
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
KR20070113295A (ko) 2005-03-17 2007-11-28 노파르티스 아게 티로신/트레오닌 키나제 억제제, 특히 ｂ-ｒａｆ 키나제억제제로서의ｎ-[3-(1-아미노-5,6,7,8-테트라히드로-2,4,4ｂ-트리아자플루오렌-9-일)-페닐]벤즈아미드
US20070099856A1 (en) 2005-05-13 2007-05-03 Gumerlock Paul H Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
AU2006284053B2 (en) 2005-08-22 2010-04-22 Novartis Ag Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
US20080242667A1 (en) 2005-08-26 2008-10-02 Smithkline Beecham Corporation Pyrimidinyl-Pyrazole Inhibitors of Aurora Kinases
TWI387592B (zh) 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
JP2009530261A (ja) 2006-03-16 2009-08-27 ファイザー・プロダクツ・インク ピラゾール化合物
JP2009532497A (ja) 2006-04-05 2009-09-10 ノバルティス アクチエンゲゼルシャフト 癌を処置するための治療剤の組合せ
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses
AU2007296744A1 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
SI2068880T1 (sl) 2006-09-18 2012-08-31 Boehringer Ingelheim Int Postopek za zdravljenje raka, ki vsebuje mutacije EGFR
CA2663366C (en) 2006-10-02 2012-02-07 Irm Llc Compounds and compositions as protein kinase inhibitors
AU2007308045A1 (en) * 2006-10-06 2008-04-17 Irm Llc Protein kinase inhibitors and methods for using thereof
WO2008100985A2 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of lbh589 with other therapeutic agents for treating cancer
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
EA201000113A1 (ru) * 2007-08-01 2010-08-30 Пфайзер Инк. Пиразольные соединения
AU2008313622A1 (en) 2007-10-19 2009-04-23 Abbott Gmbh & Co. Kg Solid dispersion product of N-aryl urea-based drugs
AU2008323287B2 (en) * 2007-11-14 2011-07-14 Addex Pharma S.A. Imidazo[1,2-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
US8129394B2 (en) * 2008-03-21 2012-03-06 Novartis Ag Heteroaryl-substituted imidazole compounds and uses thereof
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
BRPI0916356B1 (pt) 2008-07-24 2022-08-23 Nerviano Medical Sciences S.R.L 3,4-diaril pirazois como inibidores da proteína quinase
MX2011001090A (es) 2008-07-28 2011-03-15 Gilead Sciences Inc Compuestos de inhibidor de desacetilasa de histona de cicloalquilideno y heterocicloalquilideno.
US8778929B2 (en) 2008-09-29 2014-07-15 Boehringer Ingelheim International Gmbh Substituted heteroaryl inhibitors of B-RAF
MY160340A (en) 2008-10-07 2017-02-28 Astrazeneca Uk Ltd Pharmaceutical formulation 514
US20110293750A1 (en) * 2008-11-11 2011-12-01 Yale University Activated wnt-beta-catenin signaling in melanoma
US8524707B2 (en) * 2008-12-19 2013-09-03 Nerviano Medical Sciences S.R.L. Bicyclic pyrazoles as protein kinase inhibitors
AR075180A1 (es) 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
RU2402602C1 (ru) 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Rac, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2010100127A1 (en) * 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
TWI532484B (zh) 2009-06-08 2016-05-11 艾伯維有限公司 包含凋亡促進劑之固態分散劑
US8546413B2 (en) * 2009-06-15 2013-10-01 Nerviano Medical Sciences S.R.L. Substituted pyrimidinylpyrrolopyridinone derivatives, process for their preparation and their use as kinase inhibitors
KR101256018B1 (ko) * 2009-08-20 2013-04-18 한국과학기술연구원 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
EA023942B1 (ru) 2010-01-27 2016-07-29 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. Сульфонамидные производные 3,4-диарилпиразолов в качестве ингибиторов протеинкиназы
RU2639876C2 (ru) 2010-03-30 2017-12-25 Версеон Корпорейшн Мультизамещенные ароматические соединения в качестве ингибиторов тромбина
EP2601185B1 (en) 2010-08-03 2015-10-07 Nerviano Medical Sciences S.r.l. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
EP2688572B1 (en) 2011-03-21 2017-05-03 Valcuria AB A pharmaceutical composition comprising a hdac inhibitor and a steroid and the use thereof.
CA2844407A1 (en) 2011-06-14 2012-12-20 Novartis Ag Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
BR112014011223A8 (pt) 2011-11-11 2023-01-31 Novartis Ag Método de tratar uma doença proliferativa
KR102091295B1 (ko) 2011-11-23 2020-03-19 어레이 바이오파마 인크. 제약 제제
CA2890663A1 (en) 2012-11-08 2014-05-15 Novartis Ag Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases
US10576680B2 (en) 2015-11-19 2020-03-03 The Boeing Company Modular thermoforming system

Also Published As

Publication number Publication date
CU20120034A7 (es) 2012-06-21
US8501758B2 (en) 2013-08-06
PL2727918T3 (pl) 2017-06-30
MX2012002546A (es) 2012-04-11
SMT201700036B (it) 2017-03-08
CU24110B1 (es) 2015-07-30
US20160280686A1 (en) 2016-09-29
US9593100B2 (en) 2017-03-14
EP2470526B1 (en) 2014-05-28
CY2019013I1 (el) 2019-11-27
LUC00101I2 (OSRAM) 2020-01-23
US20180297986A1 (en) 2018-10-18
EP2727918A1 (en) 2014-05-07
ECSP12011700A (es) 2012-03-30
LUC00101I1 (OSRAM) 2019-02-13
NL300973I2 (nl) 2022-05-05
TN2012000081A1 (en) 2013-09-19
HRP20170005T1 (hr) 2017-03-10
CN102725283A (zh) 2012-10-10
BR112012004453A8 (pt) 2021-06-08
US9314464B2 (en) 2016-04-19
UY32860A (es) 2011-03-31
USRE49556E1 (en) 2023-06-20
HUS1900012I1 (hu) 2019-04-29
EA201200373A1 (ru) 2012-09-28
HK1167390A1 (en) 2012-11-30
AU2010286569A1 (en) 2012-04-12
EA025222B1 (ru) 2016-12-30
WO2011025927A1 (en) 2011-03-03
US10568884B2 (en) 2020-02-25
UA112285C2 (uk) 2016-08-25
KR20120062839A (ko) 2012-06-14
CA2771775A1 (en) 2011-03-03
EP2727918B1 (en) 2016-10-12
US9850230B2 (en) 2017-12-26
US20160120866A1 (en) 2016-05-05
ZA201202020B (en) 2012-12-27
SG178351A1 (en) 2012-03-29
HN2012000441A (es) 2015-01-05
MA33604B1 (fr) 2012-09-01
AR077975A1 (es) 2011-10-05
JP2013503186A (ja) 2013-01-31
LTPA2019006I1 (lt) 2019-03-25
US20160263113A1 (en) 2016-09-15
AU2010286569B2 (en) 2013-10-10
SG10201405311TA (en) 2014-09-26
EP2470526A1 (en) 2012-07-04
US20200323852A1 (en) 2020-10-15
HUS1900013I1 (hu) 2019-04-29
LTPA2019005I1 (lt) 2019-03-25
RS53489B1 (sr) 2015-02-27
IL218084A (en) 2016-11-30
SI2470526T1 (sl) 2014-09-30
EA201500175A1 (ru) 2015-05-29
CL2012000340A1 (es) 2012-08-17
US9850229B2 (en) 2017-12-26
LTC2470526I2 (lt) 2020-04-27
US20180297985A1 (en) 2018-10-18
US10576080B2 (en) 2020-03-03
ES2492499T3 (es) 2014-09-09
US20130296318A1 (en) 2013-11-07
US20160122324A1 (en) 2016-05-05
AU2010286569C1 (en) 2019-11-28
NI201200029A (es) 2012-05-29
GT201200053A (es) 2014-03-27
CA2771775C (en) 2015-01-20
SI2727918T1 (sl) 2017-02-28
US20160280687A1 (en) 2016-09-29
CY2019014I2 (el) 2019-11-27
IN2012DN02469A (OSRAM) 2015-08-21
CY2019014I1 (el) 2019-11-27
ES2610825T3 (es) 2017-05-03
PL2470526T3 (pl) 2014-10-31
US10005761B2 (en) 2018-06-26
PE20120861A1 (es) 2012-07-14
CR20120102A (es) 2012-05-02
CN103896921B (zh) 2016-02-24
ECSP23004573A (es) 2023-04-28
SMT201400133B (it) 2014-11-10
BR112012004453A2 (pt) 2021-03-09
GEP20146102B (en) 2014-05-27
NO2019012I1 (no) 2019-03-05
ME02684B (me) 2017-06-20
SMT201700036T1 (it) 2017-03-08
DOP2012000051A (es) 2012-05-31
CY1118452T1 (el) 2017-07-12
HRP20140799T1 (hr) 2014-11-07
MY156259A (en) 2016-01-29
HUE032847T2 (hu) 2017-11-28
JO3002B1 (ar) 2016-09-05
JP2014098022A (ja) 2014-05-29
IL218084A0 (en) 2012-04-30
LUC00102I2 (OSRAM) 2024-05-21
CN102725283B (zh) 2014-02-26
US9593099B2 (en) 2017-03-14
JP6045519B2 (ja) 2016-12-14
RS55568B1 (sr) 2017-05-31
CY2019013I2 (el) 2019-11-27
KR101413392B1 (ko) 2014-06-27
BR112012004453B1 (pt) 2022-04-26
LT2727918T (lt) 2017-01-25
NL300973I1 (OSRAM) 2019-03-27
CN103896921A (zh) 2014-07-02
US20110306625A1 (en) 2011-12-15
PT2470526E (pt) 2014-09-01
NZ598924A (en) 2013-07-26
DK2727918T3 (da) 2017-01-23
NO2019011I1 (no) 2019-03-05
ME01860B (me) 2014-12-20
JP5475888B2 (ja) 2014-04-16
CO6612222A2 (es) 2013-02-01
US20230116233A1 (en) 2023-04-13
PT2727918T (pt) 2017-01-20

Similar Documents

Publication Publication Date Title
DK2470526T3 (da) Forbindelser og sammensætninger som proteinkinase-inhibitorer
CY2020023I1 (el) Αναστολεiς βητα-λακταμασων
DK2421825T3 (da) Azetidinyldiamider som monoacylglycerollipase-inhibitorer
CY2017016I1 (el) Αναστολεις πρωτεασωματος
SMT201600181B (it) Composti antiparassitari di diidroazolo e composizioni che li comprendono
DK2899191T3 (da) Oxazol-substituerede indazoler som pi3-kinaseinhibitorer
SMT201600307B (it) Composizione liposomiale
DK2634231T3 (da) Sammensætninger
EP2488022A4 (en) Compositions
SMT201500157B (it) Pirazolilaminopiridine come inibitori di fak
BRPI1013588A2 (pt) composição
BRPI0918564A2 (pt) inibidores
UY33161A (es) Composiciones plaguicidas
DK2246336T3 (da) Fibroseinhibitor
DOP2011000396A (es) Composiciones novedosas
BRPI1015474A2 (pt) composição
EP2393898A4 (en) DUST SUPPRESSORS
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
BRPI1010690A2 (pt) composições
IL208136A0 (en) Substituted dihydropyrazolones as inhibitors of hif-prolyl-4-hydroxylases
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
DE112009000197T8 (de) Schiermittelzusammensetzung
EP2483274A4 (en) ANTIMALARIA AGENTS AS AN INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE
BRPI1005290A2 (pt) composição
EP2394634A4 (en) COMPOSITION CONTAINING HESPERIDINE